FDA Pediatric Advisory Committee Meets on Post-Marketing Pediatric-Focused Safety Reviews

Live News Network
1.4K followers
1 Video View·Sep 18, 2026
The U.S. Food and Drug Administration's Pediatric Advisory Committee holds a virtual public meeting at 10 a.m. ET on Sept. 16 to discuss post-marketing pediatric-focused safety reviews as required under the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act of 2003 (PREA).
AI Generated·May contain errors
Video Summary
AI GeneratedThe FDA's Pediatric Advisory Committee (PAC) convened to review post-marketing safety reports for pediatric products across CDER, CDRH, and CBER. The meeting focused on evaluating adverse event reporting infrastructure, assessing causality in complex pediatric cases, and voting on whether to maintain routine monitoring or initiate further investigations into identified safety signals.
